Stryker Corporation
SYK · What the business does, what can go wrong, and how options sellers approach it
What it does
Stryker makes medical technology used in surgery and hospital care. Its products include hip and knee replacements, trauma and extremities implants, surgical equipment for operating rooms, endoscopy systems, hospital beds and stretchers, and neurovascular devices. It is also known for Mako, its robotic system for orthopedic surgery.
Customers are mainly hospitals and surgery centers, with surgeons often driving which products get used.
How it makes money
Stryker earns revenue in two main ways. It sells implants and single-use supplies, which hospitals buy again for each procedure. It also sells capital equipment such as surgical robots, beds, and operating room gear, which are bigger purchases that depend on hospital budgets.
Robots can create a link between the two. Once a hospital installs a system, it tends to keep buying the matching implants and supplies. Acquisitions have also been a regular way the company adds product lines.
Why investors own it
Investors often view Stryker as a steady way to own long-term demand for surgery. Aging populations and a steady need for joint and other procedures support volume. The company holds a strong position in orthopedics and operating room equipment, and surgeon familiarity makes switching harder. Some owners also like the recurring nature of implant and supply sales and a history of paying a dividend.
What can go wrong
- Elective procedures can be delayed when hospitals face staffing shortages or patients face economic pressure.
- Competition from other large orthopedic and medical device makers is intense.
- Hospitals can push back on pricing.
- Product recalls, regulatory problems, or litigation can hurt results and reputation.
- Acquisitions may be hard to integrate or may not deliver what was expected.
- Currency swings affect its international sales.
What to watch
- Organic sales growth (excluding acquisitions and currency)
- Procedure volumes in knee and hip
- Mako robot installations and usage
- Operating margin trends
- Product approvals and recalls
- Acquisition announcements
- Hospital capital spending trends
Options income angle
Options on SYK are generally liquid, especially near-the-money contracts in the nearest few expirations, though trading is lighter than in the largest megacap stocks. Implied volatility tends to rise ahead of quarterly earnings and when news touches procedure volumes, acquisitions, or regulatory issues. One caution for anyone selling premium: a sharp move after earnings or a product problem can overwhelm the premium collected, and covered calls can cap gains if the shares rally strongly.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 11, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Stryker reported net sales of $25,116 million for 2025, up 11.2%, and net earnings of $3,246 million. Growth was helped by the Inari acquisition, which the company paid for as part of $4,960 million spent on acquisitions. The filing also points to an open German tax dispute, hip-implant product liability cases and a tariff-sensitive supply chain.
How the business did
- Net sales rose 11.2% as reported. Excluding acquisitions and divestitures, sales grew 10.3% in constant currency (growth with exchange-rate swings removed). The company attributes most of the gain to higher unit volume, with 0.4% from higher prices.
- MedSurg and Neurotechnology sales rose 15.7% to $15,647 million, and the Vascular line rose 50.6% to $1,968 million after the Inari deal. Orthopaedics rose only 4.3% to $9,469 million, as Spinal Implants sales fell 73.9% after that business was sold in April 2025.
- Net earnings were $3,246 million, or $8.40 per diluted share, versus $2,993 million, or $7.76, in 2024. Adjusted net earnings per diluted share were $13.63, up 11.8%. The effective tax rate was 28.1% versus 14.3%, driven by transfers of intellectual property between tax jurisdictions. Interest expense rose to $607 million from $409 million after new debt issuance.
- Operating cash flow was $5,044 million versus $4,242 million. The company paid $1,284 million in dividends, or $3.36 per share, and issued new senior notes while repaying maturing ones.
Risks specific to this company
- German tax dispute: The German tax authority issued assessments of $754 million for tax years 2010 through 2017, with $11 million more expected. The company will contest them and may seek foreign tax credits that might not fully offset any extra tax.
- Hip product liability: The company is a defendant in cases over its Rejuvenate and ABGII Modular-Neck hip stems, LFIT Anatomic CoCr V40 femoral heads and Wright legacy hip products. Outcomes are described as unpredictable, and new EU rules add class-action exposure.
- Inari goodwill: Goodwill (the premium paid over the fair value of acquired assets) for the Peripheral Vascular unit was $3,203 million. Its fair value exceeded its carrying amount by only 12%, and a 100 bps increase in the discount rate would produce an impairment charge of $198 million.
- Supply chain and tariffs: Several materials and services, including sterilization, come from a single source. The company has lost sales when it could not meet demand, though the impact has not been material, and it says new tariffs could hurt supply and costs.
- Pricing pressure: Governments and insurers push prices down, and China uses volume-based procurement to cut device prices. Hospital consolidation gives buyers more bargaining power.
- Debt load: Scheduled debt repayments total $15,973 million, including $1,000 million in 2026. The company says its investment-grade ratings should let it refinance as needed.
What management is watching
- Tariffs, which the company expects to keep raising certain product costs and to weigh on demand and supply chains.
- Capital allocation, ranked as acquisitions first, then dividends, then share repurchases, with a stated goal of sales growth at the high end of the medical technology industry.
- Gross margin mix. Management expects segment mix to hurt margins for the foreseeable future, because MedSurg and Neurotechnology, which has lower gross margins, should grow faster than Orthopaedics.
- Tax rules, including the January 2026 OECD guidance on Pillar 2 minimum-tax safe harbors, which could change tax expense.
- Measures it points investors to: constant-currency sales growth, organic sales growth and adjusted net earnings per diluted share. These adjusted figures exclude items such as acquisition costs and intangible amortization, and management bases some incentive pay on them.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Stryker grew third-quarter sales 7.7%, driven mainly by higher unit volume, but reported net earnings fell to $753 million from $859 million. The drop came from a $293 million goodwill impairment (a write-down of the value the company paid for an acquired business) in its Peripheral Vascular unit. On the company's adjusted measures, which strip out items like this one, earnings per share rose 10.3%.
How the business did
- Quarter: Net sales were $6,520 million. Net earnings per diluted share were $1.96, against $2.22 a year earlier. Adjusted net earnings per diluted share were $3.52. Operating margin was 15.9%, versus 18.7%, while adjusted operating margin rose 60 basis points (hundredths of a percentage point) to 26.2%.
- Year to date: Net sales growth was 6.6%. Net earnings were $2,774 million, or $7.19 per diluted share, versus $6.20. Adjusted earnings per share were $9.81, up 7.1%.
- Segments: MedSurg and Neurotechnology net sales rose 9.2%, led by Endoscopy at 13.9%. Orthopaedics rose 5.7%, with Ortho Tech up 15.8% and Knees up 1.1%. Hips declined, at (1.0)%.
- Margins and other items: Gross margin rose to 65.2% from 63.6%, mainly because less inventory marked up to fair value in acquisitions was being expensed. Other income was $106 million, versus $51 million, due to intellectual property licensing income. The tax rate was 24.5% versus 16.5%, because the impairment is not tax deductible.
- Cash and capital return: Nine-month operating cash flow was $3,303 million, versus $2,901 million. Financing uses included $1,000 million to repay maturing notes, $1,000 million of share repurchases and dividends. Cash, short-term investments and marketable securities were $3,271 million, versus $4,100 million at December 31, 2025.
What management is watching
- Peripheral Vascular: The unit faces near-term operational and supply constraints and a longer expected path to growth. Its goodwill was approximately $3,259 million at September 30, 2026. Management says further impairment charges could be required if the unit misses its projections or if the discount rate rises. A 100 bps increase in the discount rate would add an incremental charge of $823 million.
- Margin mix: Management expects segment mix to hurt gross margin for the foreseeable future, as it anticipates faster sales growth in lower-margin MedSurg and Neurotechnology than in Orthopaedics.
- Cybersecurity incident: The incident first reported on March 11, 2026 caused idle production time that raised manufacturing costs. The filing lists its effect on operations and financial results as an uncertainty.
- Measures and buybacks: Management points investors to constant currency and organic sales growth and to adjusted earnings measures, which exclude items it considers not indicative of core operations. In October 2026 the board added $3,000 million to the share repurchase program, bringing the total authorization to $3,033 million.
Follow SYK in Kortex
The Kortex app shows SYK's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.